stockportfolio.pro
Travere Therapeutics, Inc. (TVTX)
Healthcare · Biotechnology · NasdaqGM
Travere Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $133.59M | $154.94M | $164.25M | $175.34M | $198.32M | $131.84M | $109.46M | $145.24M | $233.18M | $490.73M |
| Gross profit | $129.04M | $151.33M | $158.72M | $170.10M | $192.19M | $128.02M | $105.04M | $133.79M | $225.43M | $480.39M |
| Net income | $-47.90M | $-59.73M | $-102.68M | $-146.43M | $-169.43M | $-180.09M | $-278.48M | $-111.40M | $-321.55M | $-25.55M |
| Net margin | -35.9% | -38.6% | -62.5% | -83.5% | -85.4% | -136.6% | -254.4% | -76.7% | -137.9% | -5.2% |
Source: Travere Therapeutics, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
Explore 16 years of Travere Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TVTX in your portfolio →
Travere Therapeutics, Inc. financial history by metric
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Travere Therapeutics, Inc. — frequently asked questions
What is Travere Therapeutics, Inc.'s revenue?
Travere Therapeutics, Inc. (TVTX) reported revenue of $490.73M for fiscal year 2025, up 110.5% from the prior year, according to its SEC filings.
Is Travere Therapeutics, Inc. profitable?
No — TVTX reported a net loss of $-25.55M in fiscal 2025.
What is TVTX's P/E ratio?
Travere Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Travere Therapeutics, Inc. growing?
TVTX's revenue grew at roughly 19.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Travere Therapeutics, Inc. have?
As of fiscal year 2025, TVTX carried roughly $311.72M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Travere Therapeutics, Inc.'s gross margin?
TVTX's gross margin was 97.9% in fiscal 2025 — gross profit of $480.39M on revenue of $490.73M.
What is Travere Therapeutics, Inc.'s market cap?
Travere Therapeutics, Inc. (TVTX) has a market capitalization of about $4.46B, based on the latest data in our nightly-refreshed cache.
When does Travere Therapeutics, Inc.'s fiscal year end?
TVTX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Travere Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.